Oak Clinic-Multiple Sclerosis — Uniontown, Ohio

Oak Clinic-Multiple Sclerosis is a clinical research site located in Uniontown, Ohio, United States 44685.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Oak Clinic-Multiple Sclerosis has participated in 1 clinical trials.

Therapeutic areas: Relapsing-remitting Multiple Sclerosis.

Sponsors: IMS HEALTH GmbH & Co. OHG.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Uniontown

Browse all research sites in Ohio · View every site in Uniontown

• Barberton Hospital
• Research Site
• Oak Clinic for Multiple Sclerosis
• Oak Clinic
• Investigational Site Number 1058
• Novartis Investigative Site
• Teva Investigational Site 13477
• Teva Investigational Site 10704
• Teva Investigational Site 1318
• Teva Investigational Site 12970
• Carp Cosmetic Surgery

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Oak Clinic-Multiple Sclerosis?

Oak Clinic-Multiple Sclerosis has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Oak Clinic-Multiple Sclerosis conducted?

Oak Clinic-Multiple Sclerosis has 1 clinical trials on record. Their work covers Relapsing-remitting Multiple Sclerosis.

Is Oak Clinic-Multiple Sclerosis accredited by Crixeo Clinical Trials?

Oak Clinic-Multiple Sclerosis has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Oak Clinic-Multiple Sclerosis?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.